Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (Menveo) Vaccination in Children 2 Through 10 Years of Age
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions
- Sponsors Novartis Vaccines
- 14 Jul 2017 Results (n=327) analysing safety, published in the Pediatric Infectious Disease Journal.
- 04 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.